Cardio Genetic Opportunity Selah Genomics recently launched a cardiovascular genetic test in partnership with Greenville Health System to identify individuals at risk of sudden cardiac death, presenting a clear entry point to hospital networks and cardiology departments for co-developed diagnostic offerings and payer-supported testing programs.

Oncology and Infections Expansion The company emphasizes oncology and infectious disease in its diagnostic portfolio, indicating potential cross-sell opportunities to cancer centers and infectious disease divisions within hospitals that are increasingly adopting molecular and genomic diagnostics to guide therapy selection and monitoring.

Pharma Collaboration Selah’s services support early stage drug development, clinical trials, and regulatory processes, suggesting upsell opportunities with pharmaceutical sponsors and CROs seeking companion diagnostics, biomarker validation, and trial-ready genomic assays.

Private to Growth With revenue in the low millions and modest funding, there is potential for strategic partnerships or targeted funding rounds to scale lab capacity, expand service offerings, and accelerate commercialization through hospital systems and biotech alliances.

Tech-Enabled Diagnostics Current tech stack and cloud-enabled diagnostic capabilities point to opportunities to bundle sequencing, data analytics, and regulatory-compliant reporting for health systems seeking integrated, scalable genomic testing platforms with streamlined workflow and patient data management.